Logo

PRCT

PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics Corporation • NASDAQ
$31.68 ▲ 0.00% (+0.00)
Market Cap $1.77 B
52w High $99.60
52w Low $27.80
Dividend Yield 0%
P/E -20.71
Volume 423.73K
Outstanding Shares 55.88M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $83.327M ▲ $77.198M ▲ $-21.411M ▼ -25.695% ▼ $-0.38 ▼ $-19.793M ▼
Q2-2025 $79.182M ▲ $73.935M ▲ $-19.578M ▲ -24.725% ▲ $-0.35 ▲ $-17.095M ▲
Q1-2025 $69.162M ▲ $71.599M ▲ $-24.737M ▼ -35.767% ▼ $-0.45 ▼ $-22.385M ▼
Q4-2024 $68.236M ▲ $63.382M ▲ $-18.856M ▲ -27.634% ▲ $-0.35 ▲ $-16.434M ▲
Q3-2024 $58.37M $59.338M $-20.974M -35.933% $-0.4 $-18.506M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $294.281M ▼ $511.541M ▼ $131.265M ▲ $380.276M ▼
Q2-2025 $302.717M ▼ $513.054M ▼ $127.258M ▼ $385.796M ▼
Q1-2025 $316.207M ▼ $519.375M ▼ $130.218M ▼ $389.157M ▼
Q4-2024 $333.725M ▲ $534.017M ▲ $131.797M ▼ $402.22M ▲
Q3-2024 $196.762M $374.142M $132.924M $241.218M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-21.411M ▼ $-6.635M ▲ $-2.868M ▼ $1.077M ▼ $-8.436M ▲ $-9.503M ▲
Q2-2025 $-19.579M ▲ $-15.043M ▲ $-2.802M ▼ $4.378M ▲ $-13.49M ▲ $-17.845M ▲
Q1-2025 $-24.737M ▼ $-16.98M ▲ $-1.836M ▼ $1.298M ▼ $-17.518M ▼ $-18.816M ▲
Q4-2024 $-18.856M ▲ $-32.391M ▼ $-1.174M ▼ $170.528M ▲ $136.963M ▲ $-33.565M ▼
Q3-2024 $-20.974M $-18.8M $-246K $1.715M $-17.331M $-19.046M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily over the past several years, but the company is still in an early, scale-up phase where sales are relatively small compared with its operating costs. Gross margins are positive and improving, which suggests the core product economics are attractive once volume grows. However, operating losses remain sizable, and the business is not yet close to break-even. Net losses and per-share losses have been persistent, though they show signs of gradually narrowing as revenue scales. Overall, this looks like a classic high-growth medtech profile: strong top-line momentum but still firmly loss-making as the company invests in commercial expansion and R&D.

Balance Sheet

Balance Sheet The balance sheet shows a company funded largely by equity with a solid cash cushion relative to its size and only modest debt. Total assets have grown meaningfully over time, driven mainly by cash raised and investments in the business. Equity has moved from negative several years ago to clearly positive, reflecting capital infusions and the build-out of operations. Debt levels appear manageable and do not dominate the capital structure. In simple terms, the company looks reasonably well-capitalized for a growth-stage medtech firm, but its future strength will depend on how long current cash can support ongoing losses.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting the gap between revenue and spending on sales, marketing, and R&D. Free cash flow is also negative, with only modest capital spending, which means most of the cash burn is from running and growing the business rather than heavy equipment build-out. This pattern is typical for a company still building its installed base and clinical footprint. The key question going forward is whether revenue growth and improving margins can outpace this burn rate before additional external funding is needed.

Competitive Edge

Competitive Edge PROCEPT operates in a focused niche within surgical robotics, targeting urological conditions, especially enlarged prostate. Its Aquablation therapy and associated robotic systems offer a differentiated, heat-free, image-guided approach that aims to improve outcomes and reduce side effects. The company has built a moat through strong clinical data, a patent portfolio, and a recurring consumables model that deepens relationships with hospitals as the installed base grows. At the same time, it operates in a broader market that includes much larger medical device players, which brings both validation and competitive pressure. Reimbursement, surgeon training, and hospital adoption curves remain important execution risks, even with the current clinical and technological edge.

Innovation and R&D

Innovation and R&D Innovation is at the core of PROCEPT’s strategy. Aquablation therapy itself is a novel approach, and the company has continued to advance it with systems like HYDROS, which layers in artificial intelligence and next-generation imaging to assist surgeons and streamline procedures. The company also pursues long-term clinical programs, such as trials exploring Aquablation for prostate cancer, supported by an FDA Breakthrough Device designation. This indicates a willingness to invest heavily in R&D and clinical evidence to expand indications and strengthen the value proposition. The upside is a potentially much larger addressable market; the trade-off is higher upfront spending, longer timelines, and regulatory and clinical outcome uncertainty.

Summary

Overall, PROCEPT BioRobotics presents as an early-stage, high-growth medical device company with a focused technological edge in urological robotics. The income statement shows strong revenue growth but ongoing, meaningful losses as the company scales. The balance sheet is relatively healthy for this stage, supported by solid cash and modest debt, while cash flows highlight a clear but manageable burn tied to growth investments. Competitively, the company benefits from differentiated technology, supportive clinical data, and a recurring revenue model, yet it faces intense competition and adoption risks typical of medtech. Its heavy emphasis on innovation, including AI-enabled systems and expansion into prostate cancer, offers substantial long-term opportunity but comes with execution and regulatory uncertainty. This is a story of promising technology transitioning toward broader commercial maturity, with financials that reflect that transition phase.

NEWS

November 20, 2025 · 4:03 PM UTC

PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025

Read more

November 4, 2025 · 4:03 PM UTC

PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance

Read more

October 15, 2025 · 4:03 PM UTC

PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025

Read more